EGFR Mutated Non Small Cell Lung Cancer

Dr. McKenna: How do we apply genomic assays to our lobulars? We know that they're a little less chemo sensitive and you know, our lobular breast cancer patients don't get any less toxicity from chemo. They get all the same toxicities, but is it benefiting them to the same degree as our invasive ductels? Dr. Heeke: It's such a fantastic question and something that we struggle with our patients. So I completely agree, I think it's not unreasonable to consider a genomic assay.